Paris – France – September 25 2024, 4:00 pm CET – The European Microbiome Innovation for Health (EMIH) association
Microbiome Times Magazine, the microbiome industry’s leading B2B publication, is pleased to announce its collaboration with the coalition groups European Microbiome Innovation for Health (EMIH) and Microbiome Therapeutics Innovation Group (MTIG) for its upcoming Microbiome Times Partnering Forum.
The meeting takes place at the impressive Dome Eventhall, 18-19 March in Brussels, bringing together stakeholders from interdisciplinary backgrounds to accelerate microbial product and tech innovations. Free-to-attend for start-ups, academic innovators, investors and healthcare companies, the Forum aims to connect decision-makers spanning the global microbial ecosystem to propel deal-making and R&D partnerships.
Several important themes were identified as focus areas of the meeting:
- Antimicrobial Resistance and One Health
- Women’s Health
- Obesity & Metabolic Health
- Cancer
- Skin health
- Longevity
- Nutrition & Digestive Health
Both EMIH and MTIG are making collaborative efforts in their respective territories to accelerate microbiome therapeutic product development. The Forum will ensure that the coalitions’ members, who are at the forefront of microbiome innovation, have a platform to share their vision and forge partnerships:
The microbiome-based therapies sector has specific challenges like for any emerging field. Recent progress towards late-stage clinical trials is encouraging and we see signs of increased maturity. In this context, unity is strength. The Microbiome Times Partnering Forum is a unique opportunity to highlight key industry players and foster fruitful collaborations that can advance this critical field.
Explains Hervé Affagard, President of EMIH and CEO of MaaT Pharma.
MTIG members are committed to fostering dialogue with a broad range of stakeholders in the microbiome space to accelerate collaboration and innovation with the expressed purpose of alleviating serious unmet medical needs, benefiting patients worldwide. We look forward to supporting the inaugural Microbiome Times Partnering Forum and believe this event will serve as a venue to do just that.
Adds Nikole Kimes, Chairman of MTIG and CEO of Siolta Therapeutics.
Nick Gallo, Director of the Microbiome Times Partnering Forum invites all those who have an interest in accelerating innovation in the field to attend:
We invite everyone with an interest in developing microbial-based solutions for human health to support this new initiative by joining us in Brussels, 18-19 March.
We are thrilled to partner with EMIH and MTIG, which, together with our industry-leading advisory board, is enabling us to develop a program consisting of top-level speakers from pharma & healthcare companies, start-ups, public sector initiatives and research centers, and also, ensure that key decision-makers are in attendance.
About The Microbiome Therapeutics Innovation Group
The Microbiome Therapeutics Innovation Group (MTIG) is a coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs. The human microbiome is one of the new frontiers of medical innovation that has the potential to benefit patients suffering from numerous diseases afflicting millions of patients and consuming billions of dollars of healthcare resources. MTIG is committed to working with stakeholders who share in our mission and seek tangible policy and regulatory solutions in the emerging microbiome arena. Through a collective voice, the MTIG membership works together to enhance the regulatory, investment, and commercial environment to accelerate microbiome therapeutic product development and enable the field to reach its potential to benefit patients.
Today, MTIG is comprised of eleven microbiome therapeutics companies: BiomeSense, Biose Industrie, Freya Biosciences, MaaT Pharma, Microba Life Sciences, Rebiotix Inc., a Ferring Company, Seres Therapeutics, Siolta Therapeutics, and Vedanta Biosciences. For more information, visit www.microbiometig.org.
About European Microbiome Innovation for Health
The European Microbiome Innovation for Health (EMIH) is an independent coalition within the European Union, the United Kingdom, and Switzerland, currently comprising 20+ major players from the public and private sectors. From the laboratory to the patient’s bedside, EMIH covers the entire value chain of the microbiome industry. Its goal is to position Europe as a global leader in the development, production, and commercialization of microbiome-based therapeutic innovations.
EMIH members include Bioaster, Biocodex, BioGaia, Biofortis, Biose Industrie, Eligo Bioscience, GMT Science, INRAe, Lallemand Health Solutions, Life Avocats, Enosis Santé, EnteroBiotix, Pelican Health, MaaT Pharma, mbiomics, Microbiotica, Microbiome Foundation, MRM Health, Nexbiome, Novobiome, Seventure Partners and SwipeBiome. For more information, please visit www.europeanmicrobiome.org
European Microbiome Innovation for Health Contacts
Media – E-mail: p.richaud@europeanmicrobiome.org
Memberships & Applications – E-mail: contact@europeanmicrobiome.org
